PA
RCKT icon

Parallel Advisors’s Rocket Pharmaceuticals RCKT Stock Holding History

Parallel Advisors’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.88K Sell
842
-3,206
-79% -$10.7K ﹤0.01% 3421
2026
Q1 		$14.5K Buy
4,048
+3,997
+7,837% +$15.9K ﹤0.01% 2605
2025
Q4 		$179 Sell
51
-228
-82% -$781 ﹤0.01% 3521
2025
Q3 		$910 Buy
279
+49
+21% +$154 ﹤0.01% 3245
2025
Q2 		$564 Sell
230
-802
-78% -$4.06K ﹤0.01% 3293
2025
Q1 		$6.88K Buy
1,032
+44
+4% +$435 ﹤0.01% 2573
2024
Q4 		$12.4K Buy
988
+929
+1,575% +$14K ﹤0.01% 2342
2024
Q3 		$1.09K Buy
+59
New +$1.21K ﹤0.01% 3012
2022
Q2 		– Sell
-293
Closed -$5K – 3288
2022
Q1 		$5K Buy
+293
New +$5.06K ﹤0.01% 2315
2021
Q4 		– Sell
-93
Closed -$3K – 3251
2021
Q3 		$3K Sell
93
-50
-35% -$1.82K ﹤0.01% 2589
2021
Q2 		$6K Buy
143
+128
+853% +$5.56K ﹤0.01% 2245
2021
Q1 		$1K Buy
+15
New +$824 ﹤0.01% 2678

Other funds holding RCKT

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Parallel Advisors's RCKT Position: Q2 2026 in Review

Parallel Advisors reduced its Rocket Pharmaceuticals (RCKT) stake by 79% in Q2 2026, selling an estimated $10.7K and leaving 842 shares worth $2.88K. The position accounts for ﹤0.01% of the portfolio, ranked #3421.

Parallel Advisors first reported a position in RCKT in Q1 2021 and has held it in 12 quarters since. The position peaked at $14.5K in Q1 2026. 180 funds tracked by Wall St. Rank hold RCKT as of Q2 2026.

  • Parallel Advisors held 842 shares of Rocket Pharmaceuticals worth $2.88K as of Q2 2026.
  • Parallel Advisors sold 3,206 Rocket Pharmaceuticals shares in Q2 2026, an estimated $10.7K.
  • Rocket Pharmaceuticals made up ﹤0.01% of Parallel Advisors's portfolio in Q2 2026, its #3421 holding.
  • Parallel Advisors first reported a position in Rocket Pharmaceuticals in Q1 2021 and has held it in 12 quarters since.
  • Parallel Advisors's Rocket Pharmaceuticals position peaked at $14.5K in Q1 2026.
  • 180 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q2 2026.

Based on Parallel Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.